GTx, Inc.
3 N. Dunlap Avenue, Third Floor
Memphis
Tennessee
38163
United States
Tel: 901-523-9700
Fax: 901-523-9772
Website: http://www.gtxinc.com/
287 articles about GTx, Inc.
-
GTX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of GTx, Inc. - GTXI
3/11/2019
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC are investigating the proposed merger of GTx, Inc. with Oncternal Therapeutics, Inc. in a stock-for-stock transaction.
-
No employees of GTx are expected to remain with the new company once the merger is complete. Oncternal will begin to trade on the Nasdaq under the ticker symbol ONCT.
-
GTx Reports Third Quarter 2018 Financial Results and Provides Corporate Update
10/22/2018
GTx, Inc. today reported financial results for the third quarter ended September 30, 2018, and provided a corporate update.
-
GTx, Inc. to Participate in the Baird 2018 Global Healthcare Conference
8/30/2018
GTx, Inc. today announced that Robert J. Wills, PhD, Executive Chairman, and other senior executive management team members will present a company overview at the Baird 2018 Global Healthcare Conference on Thursday, September 6, 2018 at 9:05 am ET in New York.
-
GTx Provides Corporate Update and Reports Second Quarter 2018 Financial Results
8/14/2018
Completed patient enrollment in the ASTRID Trial, a Phase 2 double-blinded, placebo-controlled clinical trial of enobosarm in Stress Urinary Incontinence
-
Six biotechs will end the month of June as new additions to the Russell Indexes. Approximately $9 trillion in assets are benchmarked against Russell U.S. Indexes, which are reconstituted annually.
-
GTx, Inc. to Participate in the Jefferies 2018 Global Healthcare Conference
5/31/2018
GTx, Inc. announced that Robert J. Wills, PhD, Executive Chairman, will present a company overview at the Jefferies 2018 Global Healthcare Conference.
-
GTx Updates Phase 2 Enobosarm Clinical Trial Results in Stress Urinary Incontinence at 2018 AUA Annual Meeting
5/18/2018
GTx, Inc. (Nasdaq: GTXI) today released additional data supporting the durability of the response to a 12-week treatment with enobosarm 3 mg in an open-label, Phase 2 proof-of-concept clinical trial evaluating enobosarm in postmenopausal women with stress urinary incontinence (SUI)...
-
GTx Provides Corporate Update and Reports First Quarter 2018 Financial Results
5/15/2018
Top-line results from the ASTRID Trial expected early in the fourth quarter of 2018
-
GTx Announces Early Completion of Patient Enrollment in the ASTRID Trial, a Phase 2 Clinical Trial of Enobosarm in Stress Urinary Incontinence
4/9/2018
Top-line results from placebo-controlled clinical trial expected early in the fourth quarter of 2018
-
GTx Provides Corporate Update and Reports Fourth Quarter and Full Year 2017 Financial Results
3/12/2018
GTx, Inc. reported financial results for the fourth quarter and year ended December 31, 2017 and highlighted recent accomplishments and upcoming milestones.
-
GTx Announced New Data Demonstrating Enobosarm’s Potential to Treat Stress Urinary Incontinence at SUFU 2018
3/5/2018
MRI results show increases in pelvic floor muscle and urethral muscle diameter supporting enobosarm’s mechanism of action.
-
GTx Provides Corporate Update and Reports Third Quarter 2017 Financial Results
11/15/2017
During the quarter, GTx raised net proceeds of $45.6 million in a private placement of its common stock and warrants to purchase its common stock.
-
GTx, Inc. Announces Closing Of $48.5 Million Private Placement
10/2/2017
-
GTx, Inc. Snags $48.5 Million
9/26/2017
-
GTx, Inc. Announces Positive Preliminary Results From Ongoing Phase II Proof-Of-Concept Clinical Trial In Women With Stress Urinary Incontinence
6/12/2017
-
GTx, Inc. Announces Acceptance Of An Abstract On Preliminary Results From Phase II Clinical Trial In Women With Stress Urinary Incontinence At The International Continence Society Annual Meeting
5/11/2017
-
GTx, Inc. Announces Results From Preclinical Studies Of Sarms In Duchenne Muscular Dystrophy Models Published In Human Molecular Genetics
5/3/2017
-
GTx, Inc. Provides Corporate Update And Reports Fourth Quarter And Year-End 2016 Financial Results
3/15/2017
-
GTx, Inc. To Report Fourth Quarter And Full Year 2016 Financial Results On March 15, 2017
3/7/2017